Skip to main content

Lymphoid Reaction Observed in Eczema Patients Receiving Dupilumab

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Oct. 30, 2023 -- For adults with atopic dermatitis (AD) receiving dupilumab treatment, a reversible lymphoid reaction (LR) has been observed, which mimics cutaneous T-cell lymphoma (CTCL), according to a study published online Oct. 18 in JAMA Dermatology.

Celeste M. Boesjes, M.D., from the University Medical Center Utrecht in the Netherlands, and colleagues conducted a retrospective observational case series involving adult patients with AD treated with dupilumab to examine the clinical and histopathological features of patients clinically suspected for CTCL.

The study included 14 patients suspected for CTCL with deterioration of symptoms during dupilumab treatment. The researchers found that three of these were retrospectively diagnosed with preexistent mycosis fungoides (MF) and 11 were diagnosed with an LR. The patients diagnosed with an LR showed MF-like symptoms, but had different histopathologic findings, including sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section, a dysregulated CD4:CD8 ratio, and overexpression of CD30, without CD2/CD3/CD5 loss. There was a median of four months to clinical worsening. In all patients, posttreatment biopsies showed complete clearance of the LR.

"Clinical and histopathologic recognition of an LR is important, and treatment discontinuation is recommended in these patients," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

Stigma Affects Quality of Life in Children With Chronic Skin Conditions

TUESDAY, April 30, 2024 -- Health care professionals should consider stigmatization and bullying in assessing the social and mental health of children and adolescents with chronic...

AAD: Lebrikizumab Shows Efficacy in Skin-of-Color Patients With Atopic Dermatitis

MONDAY, March 18, 2024 -- Lebrikizumab demonstrates improvement in skin clearance and itch relief in patients with skin of color and moderate-to-severe atopic dermatitis...

Atopic Dermatitis in Children Tied to Learning, Memory Difficulties

TUESDAY, March 12, 2024 -- Pediatric atopic dermatitis (AD) is associated with greater odds of reported difficulties in learning and memory, but this association is driven by...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.